Bile acids and microbes in metabolic disease

被引:10
作者
Sah, Dhiraj Kumar [1 ]
Arjunan, Archana [1 ]
Park, Sun Young [2 ]
Jung, Young Do [1 ,3 ]
机构
[1] Chonnam Natl Univ, Dept Biochem, Gwangju 501190, South Korea
[2] Chonnam Natl Univ, Dept Internal Med, Gwangju 501190, South Korea
[3] Chonnam Natl Univ, Dept Biochem, 5 Hakdong, Gwangju 501190, South Korea
关键词
Bile acids; Metabolic diseases; Gut microbe; Diabetic mellitus; Obesity; Hypercholesterolemia; TYPE-2; DIABETES-MELLITUS; GLUCAGON-LIKE PEPTIDE-1; HIGH-FAT-DIET; IMPROVES GLYCEMIC CONTROL; ANION-EXCHANGE RESIN; FARNESOID-X-RECEPTOR; HUMAN GUT MICROBIOTA; COLESEVELAM HYDROCHLORIDE; INSULIN SENSITIVITY; CHENODEOXYCHOLIC ACID;
D O I
10.3748/wjg.v28.i48.6846
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Bile acids (BAs) serve as physiological detergents that enable the intestinal absorption and transportation of nutrients, lipids and vitamins. BAs are primarily produced by humans to catabolize cholesterol and play crucial roles in gut metabolism, microbiota habitat regulation and cell signaling. BA-activated nuclear receptors regulate the enterohepatic circulation of BAs which play a role in energy, lipid, glucose, and drug metabolism. The gut microbiota plays an essential role in the biotransformation of BAs and regulates BAs composition and metabolism. Therefore, altered gut microbial and BAs activity can affect human metabolism and thus result in the alteration of metabolic pathways and the occurrence of metabolic diseases/syndromes, such as diabetes mellitus, obesity/hypercholesterolemia, and cardiovascular diseases. BAs and their metabolites are used to treat altered gut microbiota and metabolic diseases. This review explores the increasing body of evidence that links alterations of gut microbial activity and BAs with the pathogenesis of metabolic diseases. Moreover, we summarize existing research on gut microbes and BAs in relation to intracellular pathways pertinent to metabolic disorders. Finally, we discuss how therapeutic interventions using BAs can facilitate microbiome functioning and ease metabolic diseases.
引用
收藏
页码:6846 / 6866
页数:21
相关论文
共 169 条
  • [1] Vancomycin-Induced Modulation of Gram-Positive Gut Bacteria and Metabolites Remediates Insulin Resistance in iNOS Knockout Mice
    Aggarwal, Hobby
    Pathak, Priya
    Singh, Vishal
    Kumar, Yashwant
    Shankar, Manoharan
    Das, Bhabatosh
    Jagavelu, Kumaravelu
    Dikshit, Madhu
    [J]. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 11
  • [2] Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin
    Aggarwal, Hobby
    Pathak, Priya
    Kumar, Yashwant
    Jagavelu, Kumaravelu
    Dikshit, Madhu
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
  • [3] A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation
    Aoki, Ryo
    Kamikado, Kohei
    Suda, Wataru
    Takii, Hiroshi
    Mikami, Yumiko
    Suganuma, Natsuki
    Hattori, Masahira
    Koga, Yasuhiro
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [4] Probiotics: Interaction with gut microbiome and antiobesity potential
    Arora, Tulika
    Singh, Satvinder
    Sharma, Raj Kumar
    [J]. NUTRITION, 2013, 29 (04) : 591 - 596
  • [5] Effect of daily consumption of probiotic yoghurt on lipid profiles in pregnant women: a randomized controlled clinical trial
    Asemi, Zatollah
    Samimi, Mansoreh
    Tabasi, Zohreh
    Talebian, Parisa
    Azarbad, Zohreh
    Hydarzadeh, Zahra
    Esmaillzadeh, Ahmad
    [J]. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2012, 25 (09) : 1552 - 1556
  • [6] The gut microbiota as an environmental factor that regulates fat storage
    Bäckhed, F
    Ding, H
    Wang, T
    Hooper, LV
    Koh, GY
    Nagy, A
    Semenkovich, CF
    Gordon, JI
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (44) : 15718 - 15723
  • [7] Bays H, 2003, EXPERT OPIN PHARMACO, V4, P779, DOI 10.1517/14656566.4.5.779
  • [8] Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin - Glucose and lipid effects
    Bays, Harold E.
    Goldberg, Ronald B.
    Truitt, Kenneth E.
    Jones, Michael R.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (18) : 1975 - 1983
  • [9] COLESEVELAM HYDROCHLORIDE ADDED TO BACKGROUND METFORMIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A POOLED ANALYSIS FROM 3 CLINICAL STUDIES
    Bays, Harold E.
    [J]. ENDOCRINE PRACTICE, 2011, 17 (06) : 933 - 938
  • [10] Projection of Gut Microbiome Pre- and Post-Bariatric Surgery To Predict Surgery Outcome
    Ben Izhak, Meirav
    Eshel, Adi
    Cohen, Ruti
    Madar-Shapiro, Liora
    Meiri, Hamutal
    Wachtel, Chaim
    Leung, Conrad
    Messick, Edward
    Jongkam, Narisra
    Mavor, Eli
    Sapozhnikov, Shimon
    Maharshak, Nitsan
    Abu-Abeid, Subhi
    Alis, Avishai
    Mahler, Ilanit
    Meoded, Aviel
    Eldar, Shai Meron
    Koren, Omry
    Louzoun, Yoram
    [J]. MSYSTEMS, 2021, 6 (03)